Synchron’s brain implant lets an ALS patient control an iPad entirely through thought
FierceBiotech - 04-Aug-2025This breakthrough shows how technology can restore independence
Synchron
Brain computer interface company
Synchron is a clinical-stage neurovascular bioelectronics medicine company. The company has pioneered an interventional neuromodulation platform and is developing the world’s first minimally-invasive motor neuroprosthesis, the Stentrode. The company is also developing endovascular neuromodulation solutions for the potential treatment of Parkinson’s disease, epilepsy, depression and hypertension, among other disorders.
July-2022: Bloomberg reported that Synchron implanted a device into the brain of an ALS patient at Mount Sinai West medical center on July 6,.
Visit website: https://www.synchronmed.com/
Details last updated 11-Nov-2020
Synchron News
Synchron challenges Neuralink with minimally invasive brain implant
PC MAG - 16-Jul-2025Stentrode lets users control devices with thoughts—implanted via blood vessels, not surgery
Precision Neuroscience raised $102M, closing its Series C funding
MobiHealthNews - 16-Dec-2024Company competes with Neuralink and Synchron to revolutionise AI-human integration
Synchron's breakthrough: paralyzed man uses brain to control Apple device
Silicon UK - 01-Aug-2024ALS patient becomes first to use apple vision pro with BCI implant
Synchron's BCI device offers new hope for communication in paralyzed patients
IEEE Spectrum - 20-Dec-2023Non-invasive neural device leads via blood vessel while Neuralink awaits human trials
Display all news
People at Synchron
